These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 7720764)

  • 1. A population and family study of CYP1A2 using caffeine urinary metabolites.
    Catteau A; Bechtel YC; Poisson N; Bechtel PR; Bonaïti-Pellie C
    Eur J Clin Pharmacol; 1995; 47(5):423-30. PubMed ID: 7720764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes.
    Bock KW; Schrenk D; Forster A; Griese EU; Mörike K; Brockmeier D; Eichelbaum M
    Pharmacogenetics; 1994 Aug; 4(4):209-18. PubMed ID: 7987405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic polymorphism of induction of CYP1A1 (EROD) activity.
    Catteau A; Douriez E; Beaune P; Poisson N; Bonaiti-Pellié C; Laurent P
    Pharmacogenetics; 1995 Apr; 5(2):110-9. PubMed ID: 7663528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites.
    Butler MA; Lang NP; Young JF; Caporaso NE; Vineis P; Hayes RB; Teitel CH; Massengill JP; Lawsen MF; Kadlubar FF
    Pharmacogenetics; 1992 Jun; 2(3):116-27. PubMed ID: 1306111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene.
    Nakajima M; Yokoi T; Mizutani M; Shin S; Kadlubar FF; Kamataki T
    Cancer Epidemiol Biomarkers Prev; 1994; 3(5):413-21. PubMed ID: 7920209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of urinary caffeine metabolites to assess biotransformation enzyme activities by reversed-phase high-performance liquid chromatography.
    Krul C; Hageman G
    J Chromatogr B Biomed Sci Appl; 1998 May; 709(1):27-34. PubMed ID: 9653923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Segregation analyses of four urinary caffeine metabolite ratios implicated in the determination of human acetylation phenotypes.
    Vincent-Viry M; Pontes ZB; Gueguen R; Galteau MM; Siest G
    Genet Epidemiol; 1994; 11(2):115-29. PubMed ID: 8013893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities.
    Relling MV; Lin JS; Ayers GD; Evans WE
    Clin Pharmacol Ther; 1992 Dec; 52(6):643-58. PubMed ID: 1458773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios.
    Begas E; Kouvaras E; Tsakalof A; Papakosta S; Asprodini EK
    Biomed Chromatogr; 2007 Feb; 21(2):190-200. PubMed ID: 17221922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) intoxication: insights into the measurement of hepatic cytochrome P450 1A2 induction.
    Abraham K; Geusau A; Tosun Y; Helge H; Bauer S; Brockmöller J
    Clin Pharmacol Ther; 2002 Aug; 72(2):163-74. PubMed ID: 12189363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Determination of caffeine metabolite for the evaluation of N-acetyltransferase, CYP1A2 and xanthine oxidase activities].
    Lu JF; Yi T; Cao XM; Zhuo HT; Ling SS
    Yao Xue Xue Bao; 1997 Nov; 32(11):813-8. PubMed ID: 11596199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NAT2 and CYP1A2 phenotyping with caffeine: head-to-head comparison of AFMU vs. AAMU in the urine metabolite ratios.
    Nyéki A; Buclin T; Biollaz J; Decosterd LA
    Br J Clin Pharmacol; 2003 Jan; 55(1):62-7. PubMed ID: 12534641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans.
    Rasmussen BB; Brøsen K
    Ther Drug Monit; 1996 Jun; 18(3):254-62. PubMed ID: 8738764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Caffeine N3-demethylation (CYP1A2) in a population with an increased exposure to polychlorinated biphenyls.
    Petersen MS; Halling J; Damkier P; Nielsen F; Grandjean P; Weihe P; Brøsen K
    Eur J Clin Pharmacol; 2006 Dec; 62(12):1041-8. PubMed ID: 17089110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of urine caffeine metabolite ratios with use of stable isotope-labeled caffeine clearance.
    Denaro CP; Wilson M; Jacob P; Benowitz NL
    Clin Pharmacol Ther; 1996 Mar; 59(3):284-96. PubMed ID: 8653991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Caffeine as a probe for CYP1A2 activity: potential influence of renal factors on urinary phenotypic trait measurements.
    Tang BK; Zhou Y; Kadar D; Kalow W
    Pharmacogenetics; 1994 Jun; 4(3):117-24. PubMed ID: 7920691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A distribution study of CYP1A2 phenotypes among smokers and non-smokers in a cohort of healthy Caucasian volunteers.
    Schrenk D; Brockmeier D; Mörike K; Bock KW; Eichelbaum M
    Eur J Clin Pharmacol; 1998 Jan; 53(5):361-7. PubMed ID: 9516038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Caffeine as a metabolic probe: exploration of the enzyme-inducing effect of cigarette smoking.
    Kalow W; Tang BK
    Clin Pharmacol Ther; 1991 Jan; 49(1):44-8. PubMed ID: 1988240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Caffeine metabolism before and after liver transplantation.
    Bechtel YC; Lelouët H; Hrusovsky S; Brientini MP; Mantion G; Paintaud G; Miguet JP; Bechtel PR
    Int J Clin Pharmacol Ther; 2001 Feb; 39(2):53-60. PubMed ID: 11270802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of the urine flow rate on some caffeine metabolite ratios used to assess CYP1A2 activity.
    Sinués B; Fanlo A; Bernal ML; Mayayo E; Soriano MA; Martínez-Ballarin E
    Ther Drug Monit; 2002 Dec; 24(6):715-21. PubMed ID: 12451287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.